Samuel Matthias was 22, embarking on a finance career and maintaining a fit lifestyle, when he began experiencing subtle symptoms that he initially dismissed. Lingering shoulder pain and unusual chest sensations were the first indicators of an aggressive, late-stage cancer: desmoplastic small round cell tumour (DSRCT), a rare sarcoma with a 10% five-year survival rate.
Initially, Matthias attributed the mild chest discomfort to exercise or stress. The symptoms, however, gradually accumulated. A persistent shoulder ache and a noticeable enlarged lymph node in his neck prompted a visit to his general practitioner. While doctors monitored the situation and performed an ultrasound, the initial assessment suggested no cause for alarm, considering his youth and seemingly good health. A lingering viral infection was suggested as a possibility for the swollen lymph node.
Escalating Symptoms and Diagnosis
Months later, Matthias experienced severe chest pain, prompting his mother to urge him to seek further medical attention. A chest X-ray revealed concerning abnormalities, and he was immediately directed to the hospital. The initial radiology report described widespread metastatic disease, indicative of aggressive cancer. The diagnostic process was complex, as the cancer did not present typical symptoms. Tissue samples were eventually sent to Boston for examination by a sarcoma pathology expert, a process that took several weeks.
During this period of diagnostic uncertainty, Matthias's condition worsened. He recalled experiencing shortness of breath while playing soccer and coughing up blood, which caused significant fear. The journey involved transfers between specialist teams, including a lung cancer team and eventually to sarcoma specialists at Peter MacCallum Cancer Centre. Throughout this stressful period, Matthias relied heavily on the support of his mother and friends.
Treatment Journey and Setbacks
By the time the DSRCT diagnosis was confirmed, the cancer had spread extensively. His treatment journey, spanning over four years, involved intensive chemotherapy regimens, with hospitalization every three weeks for cycles of treatment. In September 2022, he underwent surgery for a lung lobectomy to remove the upper half of his right lung. This was followed by a period of six to seven months where scans were clear, offering a renewed sense of optimism.
However, this hope was disrupted in late 2023 when Matthias began experiencing severe migraines and numbness. Scans revealed a brain metastasis, described as being roughly the size of a tennis ball. He underwent emergency brain surgery, which was successful, allowing him to leave the hospital on New Year's Eve 2023. Following the surgery, he participated in an mRNA cancer vaccine clinical trial, which managed to control the disease for another eight months.
Financial Hurdles and Advocacy
As government-funded treatment options were exhausted, Matthias and his family faced the challenge of self-funding treatments, with one targeted therapy costing approximately $20,000. To date, they have spent over $50,000 out of pocket. Matthias highlighted the difficulties faced by patients with rare cancers, where insufficient patient numbers often prevent large clinical trials necessary for government funding, leaving potentially life-saving treatments inaccessible.
The experience has profoundly altered Matthias's life perspective, shifting his focus from a career in banking to cancer research and advocacy. He now dedicates his time to connecting with researchers, supporting young cancer patients, and raising awareness about rare cancers. He emphasizes the importance of early detection and encourages young people to take changes in their bodies seriously, regardless of age or perceived health status. Matthias continues to undergo ongoing treatment to manage his metastatic disease, approaching each scan with the understanding that recurrence is possible, but focusing on making the most of life in the interim.